FOLH1 and prostate cancer: All newly synthesized compounds were fully characterized by 1H-NMR, 13C-NMR, and HRMS; they were also tested for selective cytotoxic activity against PSMA-expressing human prostate cancer cell LNCaP-FGC and non-PSMA-expressing cells HepG2, Hela, MCF-7, DU145, and PC-3, respectively [24,25,26,27,28] and normal cells MDCK, LO2 by standard MTT assay.